No price history available.
Key financial summary
Financials in MYR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | MYRm | 417 | 515 | 179 | 155 | 147 | 148 | N/A | N/A |
| Operating profit | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | MYRm | 131 | 186 | -56 | -64 | -14 | -45 | N/A | N/A |
| EPS reported | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in MYR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Hextar Healthcare Berhad, an investment holding company, produces, sells, and exports household gloves, industrial gloves, and nitrile disposable gloves in Europe, Asia, North and South America, and internationally. The company operates through Gloves Operation, Medical Devices Operation, and Investment Holding segments. It offers latex, neoprene, and two tone gloves. The company also manufactures and trades in in-vitro diagnostics rapid test kits and enzyme-linked immunosorbent assay test kits for detection and diagnoses of infectious diseases and drug-of-abuse screening for medical professionals and the clinical diagnostic markets. In addition, it is involved in the trading of gloves, household and kitchen items, and personal protective products. Hextar Healthcare Berhad was founded in 1987 and is headquartered in Ipoh, Malaysia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hextar Healthcare Berhad (7803.KL)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Hextar Healthcare Berhad, an investment holding company, produces, sells, and exports household gloves, industrial gloves, and nitrile disposable gloves in Europe, Asia, North and South America, and internationally. The company operates through Gloves Operation, Medical Devices Operation, and Investment Holding segments. It offers latex, neoprene, and two tone gloves. The company also manufactures and trades in in-vitro diagnostics rapid test kits and enzyme-linked immunosorbent assay test kits for detection and diagnoses of infectious diseases and drug-of-abuse screening for medical professionals and the clinical diagnostic markets. In addition, it is involved in the trading of gloves, household and kitchen items, and personal protective products. Hextar Healthcare Berhad was founded in 1987 and is headquartered in Ipoh, Malaysia.